Cytokinetics Inc.

CYTKNASDAQ • USD
53.80 USD
↘ 2.33 (4.15%)🟢LIVE (AS OF 11:50 AM EST)
🟢Market: OPEN

Shares of Cytokinetics Inc. (CYTK) are trading at $53.80. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (242.2%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, CYTK is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 13, 2026.

Open?$55.29
High?$56.72
Low?$53.38
Prev. Close?$56.13
Volume?343.0K
Avg. Volume?2.0M
VWAP?$54.28
Rel. Volume?0.17x
Bid / Ask
Bid?$54.05 × 100
Ask?$61.62 × 100
Spread?$7.57
Midpoint?$57.83
Valuation & Ratios
Market Cap?7.8B
Shares Out?139.3M
Float?121.1M
Float %?97.3%
P/E Ratio?N/A
P/B Ratio?-24.35
EPS?-$5.58
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Employees
673
Market Cap
7.8B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2004-04-29
Address
350 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 624-3000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
92
Short Sent.?
48
Piotroski F-Score?3/9Weak
Altman Z-Score?-1.62Distress
Confidence?55%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?14.81%High
Short Interest?17.9M
Days to Cover?14.2
Free Float121.1M
Avg Daily Volume1.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?3.36Strong
Quick Ratio?3.36Strong
Cash Ratio?0.58Adequate
Debt/Equity?-3.59Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-24.35CHEAP▾
P/S?
Peers
100
S&P
3
69.02HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-12.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
77.39HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
242.2%STRONG▾
ROA?
S&P
3
-42.6%WEAK▾
Cash Flow & Enterprise
FCF?$-588577000
Enterprise Value?$8.8B
Fundamentals ratios updated end of day